Recursion Pharmaceuticals, Inc. (RXRX)

3.36 -0.07 (-2.04%) USD  |  NASDAQ  |  May 07, 11:55
More

Recursion Pharmaceuticals SG&A Expense (TTM) : 121.94M for March 31, 2026

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for RXRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Intellia Therapeutics, Inc. 119.80M
Tango Therapeutics, Inc. 41.51M
KalVista Pharmaceuticals, Inc. 191.34M
Ionis Pharmaceuticals, Inc. 467.79M
Quince Therapeutics, Inc. 15.05M